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Abstract The Drug-Resistant Pathogen Surveillance
Group in Pediatric Infectious Disease conducted national
surveillance for Haemophilus inﬂuenzae in 2007 (phase 3)
and 2010 (phase 4), following the previous surveillance
conducted from 2000 to 2001 (phase 1) and in 2004 (phase
2). We examined the antimicrobial susceptibility for
H. inﬂuenzae derived from clinical specimens of pediatric
patients collected nationwide from 27 institutions during
phases 3 (386 strains) and 4 (484 strains). The frequency of
b-lactamase-nonproducing ampicillin (ABPC)-resistant
(BLNAR) strains, which rapidly increased from 11.4 % in
phase 1 to 43.4 % in phase 2, has gradually decreased from
38.3 % in phase 3 to 37.8 % in phase 4. In contrast, On the
other hand, the frequency of b-lactamase-producing strains,
which continuously decreased from 8.3 % in phase 1 to
4.4 % in phase 3, has increased to 8.7 % in phase 4.
Prevalence of b-lactamase-producing clavulanic acid/
amoxicillin-resistant (BLPACR) strains, especially, has
increased from 1.6 % in phase 3 to 4.8 % in phase 4. The
oral antimicrobial agents with the lowest MIC90 were
levoﬂoxacin in both phases, and tosuﬂoxacin in phase 4
(B0.063 lg/ml), whereas for intravenous use the corre-
sponding agent was tazobactam/piperacillin in both phases
(0.125 lg/ml). There was no increase in the MIC90 of most
b-lactams between phase 3 and phase 4. In relationship to
sex, age, presence of siblings, attendance at a daycare
center, siblings’ attendance at a daycare center, and prior
administration of antimicrobial agents within 1 month, the
frequency of b-lactamase-nonproducing ABPC-intermedi-
ately resistant (BLNAI) strains ? BLNAR strains was high
(P = 0.005) in cases with prior administration of antimi-
crobial agents in phase 3.
Keywords Pediatric infectious disease  Surveillance 
Haemophilus inﬂuenzae sensitivity  Drug resistance
Introduction
Haemophilus inﬂuenzae, along with Streptococcus pneu-
moniae, is a major pathogen in respiratory tract infection
and invasive infection in children. Previously, H. inﬂuen-
zae developed resistance to ampicillin (ABPC) by pro-
ducing b-lactamase; however, since the beginning of the
2000s, there has been a rapid increase in the prevalence of
ampicillin-resistant strains that do not produce b-lacta-
mase, that is, b-lactamase-nonproducing ABPC-resistant
(BLNAR) strains [1]. With regard to the BLNAR strains,
their sensitivity to cephems and carbapenems, as well as to
ABPC, decreases as a result of mutations in the ftsI genes
that encode penicillin-binding protein (PBP) 3 [2], causing
major problems in the development of treatment strategies
T. Hoshino (&)
Division of Infectious Diseases, Chiba Children’s Hospital,
579-1 Heta-cho, Midori-ku, Chiba, Chiba, Japan
e-mail: t.hshn12@pref.chiba.lg.jp
Y. Sato
Department of Pediatrics, Fiji Heavy Industries Health Insurance
Society Ota Memorial Hospital, Ota, Japan
Y. Toyonaga
Department of Pediatrics, Sekishinkai Sayama Hospital,
Sayama, Japan
H. Hanaki
The Kitasato Institute, Kitasato University Research Center for
Anti-infectious Drugs, Tokyo, Japan
K. Sunakawa
The Kitasato Institute, Kitasato University Research
Organization for Infection Control Sciences, Tokyo, Japan
123
J Infect Chemother (2013) 19:495–503
DOI 10.1007/s10156-013-0591-z
Open access under CC BY license. 
for pediatric infection such as meningitis. The Drug-
Resistant Pathogen Surveillance Group in Pediatric Infec-
tious Disease reported that from phase 1 (2000–2001) to
phase 2 (2004) of Nationwide Surveillance there was a
rapid increase in the distribution of BLNAR strains and a
decrease in b-lactamase-nonproducing ABPC-sensitive
(BLNAS) strains [3]. It is very important to maintain an
understanding of the trends in development of drug resis-
tance in H. inﬂuenzae to be able to choose the proper
antimicrobial agent in situations where there are signiﬁcant
changes in the prevalence of drug-resistant strains. We
therefore conducted phase 3 (2007) and phase 4 (2010)
surveillance studies, following the ﬁrst two phases. Here
we report the results of these studies.
Materials and methods
Strains, antimicrobial susceptibility testing,
and capsular typing for serotype b strains
We collected H. inﬂuenzae isolated from clinical speci-
mens taken from pediatric patients at 27 institutions
nationwide, all of which participated in the Drug-Resis-
tant Pathogen Surveillance Group in Pediatric Infectious
Disease, and used the 386 strains accumulated from
January to June in 2007 for phase 3 and the 484 strains
accumulated from January to June in 2010 for phase 4.
The sources of the isolates were as follows in phase 3:
nasopharynx, 299 strains; pharynx, 51 strains; sputum, 29
strains; blood, 3 strains; nasal discharge and pus, 1 strain
for each; and unknown origin, 2 strains. Sources of iso-
lates were as follows in phase 4: nasopharynx, 396
strains; sputum, 40 strains; pharynx, 30 strains; blood, 8
strains; cerebrospinal ﬂuid, 4 strains; and unknown origin,
6 strains.
For antimicrobial susceptibility testing, we measured the
minimum inhibitory concentration (MIC) by the broth
microdilution method, complying with the Clinical and
Laboratory Standards Institute (CLSI) standards [4]. Sen-
sitivity to the following 21 drugs was tested during phase 3:
ABPC, clavulanic acid/amoxicillin (CVA/AMPC), pipera-
cillin (PIPC), tazobactam/piperacillin (TAZ/PIPC), cefa-
clor (CCL), cefditoren (CDTR), cefcapene (CFPN),
cefpodoxime (CPDX), cefdinir (CFDN), cefotaxime
(CTX), cefteram (CFTM), cefotiam (CTM), ceftriaxone
(CTRX), faropenem (FRPM), panipenem (PAPM), me-
ropenem (MEPM), azithromycin (AZM), clarithromycin
(CAM), rokitamycin (RKM), telithromycin (TEL), and
levoﬂoxacin (LVFX). During phase 4, sensitivity was tes-
ted against a total of 23 drugs including those tested during
phase 3 (other than TEL), with the following additional
drugs: tebipenem (TBPM), doripenem (DRPM), and
tosuﬂoxacin (TFLX). b-Lactamase production was deter-
mined by the nitrocephin method.
The strains were classiﬁed according to the CLSI criteria
[5]: that is, b-lactamase-nonproducing strains were classi-
ﬁed into BLNAS strains, for which the MIC for ABPC was
1 lg/ml or less; b-lactamase-nonproducing ABPC-inter-
mediately resistant (BLNAI) strains, with MIC for ABPC of
2 lg/ml; andBLNAR strains, withMIC forABPCof 4 lg/ml
or more. b-Lactamase-producing strains were classiﬁed
into b-lactamase-producing ABPC-resistant (BLPAR)
strains, with MIC for CVA/AMPC of 4 lg/ml or less; and
b-lactamase-producing CVA/AMPC-resistant (BLPACR)
strains, with MIC for CVA/AMPC of 8 lg/ml or more.
Additionally, all the strains were tested for H. inﬂuenzae
serotype b (Hib) by the polymerase chain reaction (PCR)
method [6]. Fourteen strains (3.6 %) in phase 3 and 23
strains (4.8 %) in phase 4 were detected as Hib. The
sources of Hib strains in phase 3 were as follows: naso-
pharynx, 9 strains; blood, 3 strains; and pharynx and pus, 1
strain for each. Sources of Hib strains in phase 4: naso-
pharynx, 9 strains; blood, 8 strains; cerebrospinal ﬂuid, 4
strains; and sputum and pharynx, 1 strain each.
Background factors and statistical analysis
To examine the relationship between background factors
and the development of drug resistance, the frequency of
isolation was compared between drug-resistant strains and
BLNAS strains in relationship to six background factors,
including sex, age, presence or absence of siblings, atten-
dance or nonattendance at a daycare center, siblings’
attendance or nonattendance at a daycare center, and prior
administration of antimicrobial agents within 1 month.
The standard for drug-resistant strains was the same as that
used in phase 1 and phase 2 and was deﬁned as
BLNAI ? BLNAR. The v2 test was used to identify
whether a signiﬁcant difference exists, using two-sided
testing at a 5 % level of signiﬁcance. Fisher’s exact test
was used when an expected value was less than 5.
Results
Figure 1 shows the number of strains by degrees of resis-
tance. In phase 3, there were 133 strains of BLNAS
(34.5 %), 88 strains of BLNAI (22.8 %), 148 strains of
BLNAR (38.3 %), 11 strains of BLPAR (2.8 %), and 6
strains of BLPACR (1.6 %). In phase 4, there were 161
strains of BLNAS (33.3 %), 98 strains of BLNAI (20.2 %),
183 strains of BLNAR (37.8 %), 19 strains of BLPAR
(3.9 %), and 23 strains of BLPACR (4.8 %).
Figure 2 shows the number of Hib strains by degrees of
resistance. In phase 3, there were 9 strains of BLNAS
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(64.3 %), 3 strains of BLNAI (21.4 %), 1 strain of BLNAR
(7.1 %), 1 strain of BLPAR (7.1 %), and no BLPACR
strain. In phase 4, there were 13 strains of BLNAS
(56.5 %), 4 strains of BLNAI (17.4 %), 6 strains of
BLPAR (26.1 %), and no BLNAR or BLPACR strains.
Table 1 shows the MIC50, MIC90, and MIC range of
antimicrobial agents for H. inﬂuenzae. In phase 3 with a
total of 386 strains, the oral antimicrobial agent with the
lowest MIC90 was LVFX (B0.063 lg/ml), followed by
CDTR (0.25 lg/ml). The intravenous antimicrobial agent
with the lowest MIC90 was TAZ/PIPC (0.125 lg/ml), fol-
lowed by PIPC, CTRX, and MEPM (0.25 lg/ml). In phase
4 with a total of 484 strains, the oral antimicrobial agent
with the lowest MIC90 was LVFX and TFLX (B0.063
lg/ml), followed by CDTR (0.25 lg/ml). The intravenous
antimicrobial agent with the lowest MIC90 was TAZ/PIPC
(0.125 lg/ml), followed by PIPC and CTRX (0.25 lg/ml).
Between phase 3 and phase 4, there was a twofold increase
in the MIC90 values of PAPM (2–4 lg/ml) and MEPM
(0.25–0.5 lg/ml), but there were no changes in those of
other drugs.
Table 2 shows the MIC50, MIC90, and MIC range of
antimicrobial agents for H. inﬂuenzae divided into the
following ﬁve groups by degrees of resistance, the BLNAS,
BLNAI, BLNAR, BLPAR, and BLPACR groups, respec-
tively. In the BLNAR group, the MIC50 values of the
b-lactams excluding PIPC and TAZ/PIPC were 4- to 64
fold higher, and the MIC90 values of all the agents were
2- to 4 fold higher than the values in the BLNAS group in
phase 3. In phase 4, in the BLNAR group, the MIC50
values of the b-lactams excluding PIPC and TAZ/PIPC
were 4- to 32 fold higher, and the MIC90 values of all the
agents were 2- to 8 fold higher than the values in the
BLNAS group. In both phase 3 and phase 4, the MIC50
values of PIPC and TAZ/PIPC were the same in the
BLNAS and BLNAR groups (B0.063 lg/ml).
The MIC90 values of antimicrobial agents for H. inﬂu-
enzae, categorized by degrees of resistance, are as follows:
in the BLNAS group, the oral antimicrobial agents with the
lowest MIC90 were CDTR and LVFX (B0.063 lg/ml) in
phase 3, and LVFX and TFLX (B0.063 lg/ml) in phase 4,
whereas the intravenous agent with the lowest MIC90 was
TAZ/PIPC (B0.063 lg/ml) in both phase 3 and phase 4. In
the BLNAI, BLNAR, and BLPAR groups, the oral anti-
microbial agent with the lowest MIC90 was LVFX
(B0.063 lg/ml) in phase 3, and LVFX and TFLX
(B0.063 lg/ml) in phase 4. In the BLNAI group, the
intravenous antimicrobial agent with the lowest MIC90 was
TAZ/PIPC (0.125 lg/ml) in phase 3, and PIPC and TAZ/
PIPC (0.125 lg/ml) in phase 4. In the BLNAR group, the
intravenous antimicrobial agents with the lowest MIC90
were PIPC, TAZ/PIPC, and CTRX (0.25 lg/ml) in phase 3,
and TAZ/PIPC (0.125 lg/ml) in phase 4. In the BLPAR
group, the intravenous antimicrobial agent with the lowest
MIC90 was TAZ/PIPC in both phase 3 and phase 4 (phase
3, B0.063 lg/ml; phase 4, 0.125 lg/ml). In the BLPACR
group, the oral antimicrobial agent with the lowest MIC90
was CDTR and LVFX (0.25 lg/ml) in phase 3, and LVFX
and TFLX (B0.063 lg/ml) in phase 4, whereas the intra-
venous antimicrobial agent with the lowest MIC90 was
TAZ/PIPC in both phase 3 andphase 4 (phase 3, 0.125 lg/ml;
phase 4, B0.063 lg/ml).
The frequency of isolation was compared between drug-
resistant strains and BLNAS strains in relationship to six
background factors: sex, age, presence or absence of sib-
lings, attendance or nonattendance at a daycare center,
Fig. 1 Distribution of Haemophilus inﬂuenzae strains classiﬁed by
ampicillin (ABPC) or clavulanic acid/amoxicillin (CVA/AMPC)
resistance in phases 3 and 4. BLNAS, b-lactamase-nonproducing
ABPC-sensitive strain; BLNAI, b-lactamase-nonproducing ABPC-
intermediately resistant strain; BLNAR, b-lactamase-nonproducing
ABPC-resistant strain; BLPAR, b-lactamase-producing ABPC-resis-
tant strain; BLPACR, b-lactamase-producing CVA/AMPC-resistant
strain
Fig. 2 Distribution of Haemophilus inﬂuenzae serotype b strains
classiﬁed by ampicillin (ABPC) or clavulanic acid/amoxicillin (CVA/
AMPC) resistance in phases 3 and 4. BLNAS, b-lactamase-nonpro-
ducing ABPC-sensitive strain; BLNAI, b-lactamase-nonproducing
ABPC-intermediately resistant strain; BLNAR, b-lactamase-nonpro-
ducing ABPC-resistant strain; BLPAR, b-lactamase-producing
ABPC-resistant strain; BLPACR, b-lactamase-producing CVA/
AMPC-resistant strain
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siblings’ attendance or nonattendance at a daycare center,
and prior administration of antimicrobial agents within 1
month (Table 3). In phase 3, the isolation rate of drug-
resistant strains was higher (P = 0.005) in cases with prior
administration of antimicrobial agents.
Discussion
The Drug-Resistant Pathogen Surveillance Group in Pedi-
atric Infectious Disease has continued to conduct national
surveillance for the antimicrobial susceptibility of H. in-
ﬂuenzae since 2000. The previous study reported that the
frequency of BLNAR strains dramatically increased from
28.8 % in phase 1 (2000–2001) to 59.3 % in phase 2
(2004) [3]. An ABPC MIC of 2 lg/ml or more was used as
a criterion for the identiﬁcation of BLNAR strains in phase
1 and phase 2. Had an ABPC MIC of 4 lg/ml or more been
used as in the current study, the frequency of BLNAR
strains would have decreased to 11.4 % and 43.4 % in
phases 1 and 2, respectively. Nonetheless, the distribution
of BLNAR strains still increased dramatically between
phase 1 and phase 2.
In this study, the frequency of BLNAR strains was
38.3 % in phase 3 and 37.8 % in phase 4, indicating a
downward tendency from its peak in phase 2. According to
a report on the national surveillance conducted in Spain,
the frequency of BLNAR strains gradually decreased from
13.5 % in 1996–1997 to 0.7 % in 2006–2007 [7]. Possible
reasons for the decline in the number of BLNAR strains are
changes in the number of prescriptions and clonal spread of
sensitive strains. A positive correlation between the dosage
of antimicrobial agents and the development of drug
resistance has been observed with the use of population
Table 1 Susceptibilities for Haemophilus inﬂuenzae in phase 3 and phase 4
Phase 3 Phase 4
Number of strains 386 484
MIC MIC50 MIC90 MIC range MIC50 MIC90 MIC range
ABPC 2 8 0.12–[128 2 8 B0.063–[128
CVA/AMPC 4 8 0.25–32 4 8 0.125–16
PIPC B0.063 0.25 B0.063–[128 B0.063 0.25 B0.063–[128
TAZ/PIPC B0.063 0.125 B0.063–1 B0.063 0.125 B0.063–0.25
CCL 16 64 0.25–[128 16 64 0.25–128
CDTR 0.125 0.25 B0.063–0.5 0.125 0.25 B0.063–1
CFPN 1 2 B0.063–4 1 2 B0.063–8
CPDX 2 4 B0.063–8 2 4 B0.063–8
CFDN 2 8 B0.063–16 2 8 B0.063–16
CFTM 0.5 1 B0.063–2 0.5 1 B0.063–2
CTM 8 64 B0.063–128 8 64 0.125–128
CTRX 0.125 0.25 B0.063–0.5 0.125 0.25 B0.063–0.5
CTX 0.5 1 B0.063–4 0.5 1 B0.063–4
AZM 1 2 0.125–64 1 2 B0.063–4
CAM 4 8 1–[64 4 8 0.5–32
RKM 8 16 1–32 8 16 B0.063–32
TEL 1 2 0.25–8 – – –
FRPM 2 4 B0.063–4 2 4 B0.063–8
TBPM – – – 0.25 1 B0.063–2
PAPM 1 2 B0.063–4 1 4 B0.063–8
MEPM 0.125 0.25 B0.063–1 0.125 0.5 B0.063–1
DRPM – – – 0.5 2 B0.063–4
LVFX B0.063 B0.063 B0.063–0.5 B0.063 B0.063 B0.063–0.5
TFLX – – – B0.063 B0.063 B0.063–2
ABPC ampicillin, CVA/AMPC clavulanic acid/amoxicillin, PIPC piperacillin, TAZ/PIPC tazobactam/piperacillin, CCL cefaclor, CDTR cefdi-
toren, CFPN cefcapene, CPDX cefpodoxime, CFDN cefdinir, CFTM cefteram, CTM cefotiam, CTRX ceftriaxone, CTX cefotaxime, AZM
azithromycin, CAM clarithromycin, RKM rokitamycin, TEL telithromycin, FRPM faropenem, TBPM tebipenem, PAPM panipenem, MEPM
meropenem, DRPM doripenem, LVFX levoﬂoxacin, TFLX tosuﬂoxacin
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Table 2 Suscepsibilities for Haemophilus inﬂuenzae (divided into ﬁve groups) in phase 3 and phase 4
Class BLNAS BLNAI BLNAR
Phase Phase 3 Phase 4 Phase 3 Phase 4 Phase 3 Phase 4
No. of
strains
(%)
133 (34.5) 161(33.3) 88 (22.8) 98 (20.2) 148 (38.3) 183 (37.8)
MIC MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range
ABPC 0.25 1 0.125–1 0.5 1 B0.063–1 2 2 2–2 2 2 2–2 4 8 4–16 4 8 4–8
CVA/
AMPC
0.5 2 0.25–4 0.5 2 0.125–4 4 8 1–8 4 4 1–8 8 8 2–32 4 8 2–16
PIPC B0.063 0.125 B0.063–0.5 B0.063 0.125 B0.063–0.5 B0.063 0.25 B0.063–0.5 B0.063 0.125 B0.063–0.25 B0.063 0.25 B0.063–1 B0.063 0.25 B0.063–0.5
TAZ/
PIPC
B0.063 B0.063 B0.063–0.5 B0.063 B0.063 B0.063–0.25 B0.063 0.125 B0.063–0.25 B0.063 0.125 B0.063–0.25 B0.063 0.25 B0.063–1 B0.063 0.125 B0.063–0.25
CCL 4 16 0.25–64 4 16 0.25–64 32 64 4–[128 16 64 2–128 64 128 4–to 128 32 64 2–128
CDTR B0.063 B0.063 B0.063–0.5 B0.063 0.125 B0.063–0.5 0.125 0.25 B0.063–0.5 0.25 0.25 B0.063–0.5 0.25 0.25 B0.063–0.5 0.25 0.5 B0.063–1
CFPN B0.063 0.5 B0.063–2 B0.063 0.5 B0.063–1 1 2 B0.063–4 1 2 B0.063–4 2 2 0.25–4 2 4 B0.063–8
CPDX B0.063 1 B0.063–8 B0.063 1 B0.063–4 2 8 0.25–8 2 4 0.125–8 4 4 1–8 2 4 0.25–8
CFDN 0.25 2 B0.063–8 0.5 2 B0.063–4 4 8 0.5–16 2 4 0.5–8 4 8 0.5–16 4 8 0.5–16
CFTM B0.063 0.5 B0.063–1 B0.063 0.5 B0.063–1 0.5 1 B0.063–1 0.5 1 B0.063–2 0.5 1 0.125–2 1 1 B0.063–1
CTM 2 8 B0.063–64 2 8 0.125–32 16 64 2–64 8 32 1–64 32 64 2–128 32 64 1–128
CTRX B0.063 0.125 B0.063–0.25 B0.063 0.125 B0.063–0.25 0.125 0.25 B0.063–0.5 0.125 0.25 B0.063–0.5 0.25 0.25 B0.063–0.5 0.25 0.25 B0.063–0.5
CTX B0.063 0.5 B0.063–1 B0.063 0.5 B0.063–0.5 0.5 1 B0.063–2 0.5 1 B0.063–2 0.5 2 0.125–4 1 2 B0.063–4
AZM 1 2 0.125–4 1 1 B0.063–4 1 2 0.25–4 1 2 0.125–4 1 2 0.25–4 1 2 0.125–2
CAM 4 8 1–16 4 8 0.5–32 4 8 1–16 4 16 1–16 8 8 1–16 8 8 2–16
RKM 8 16 1–32 4 16 B0.063–32 8 16 2–16 8 16 1–32 8 16 2–16 8 16 0.25–16
TEL 1 2 0.25–8 – – – 1 2 0.5–8 – – – 2 2 0.5–4 – – –
FRPM 0.5 1 B0.063–2 0.5 2 B0.063–4 2 2 0.25–4 1 2 0.25–4 2 4 0.25–4 2 4 0.5–8
TBPM – – – 0.125 0.25 B0.063–1 – – – 0.25 1 B0.063–1 – – – 0.5 1 B0.063–2
PAPM 0.5 1 B0.063–2 0.5 2 B0.063–4 1 2 0.125–4 1 4 B0.063–8 2 2 0.125–4 2 4 0.25–8
MEPM B0.063 0.125 B0.063–0.125 B0.063 0.125 B0.063–0.5 0.125 0.25 B0.063–0.5 0.25 0.5 B0.063–0.5 0.25 0.5 B0.063–1 0.25 0.5 B0.063–1
DRPM – – – 0.125 0.5 B0.063–1 – – – 0.5 1 B0.063–2 – – – 1 2 B0.063–4
LVFX B0.063 B0.063 B0.063–0.125 B0.063 B0.063 B0.063–0.5 B0.063 B0.063 B0.063–0.125 B0.063 B0.063 B0.063–0.5 B0.063 B0.063 B0.063–0.5 B0.063 B0.063 B0.063–0.125
TFLX – – – B0.063 B0.063 B0.063–2 – – – B0.063 B0.063 B0.063–
B0.063
– – – B0.063 B0.063 B0.063–0.125
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Table 2 continued
Class BLPAR BLPACR
Phase Phase 3 Phase 4 Phase 3 Phase 4
No. of strains (%) 11 (2.8) 19 (3.9) 6 (1.6) 23 (4.8)
MIC MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range MIC50 MIC90 MIC Range
ABPC 128 [128 2 to[128 32 [128 16 to[128 [128 [128 [128 to[128 [128 [128 64 to[128
CVA/AMPC 1 4 0.25–4 2 4 0.5–4 8 16 8–16 8 16 8–16
PIPC 128 [128 0.25 to[128 16 [128 2 to[128 [128 [128 [128 to[128 64 [128 8 to[128
TAZ/PIPC B0.063 B0.063 B0.063–B0.063 B0.063 0.125 B0.063–0.125 B0.063 0.125 B0.063–0.125 B0.063 B0.063 B0.063–0.125
CCL 8 32 2–64 8 32 2–32 64 128 4–128 32 64 16–128
CDTR B0.063 0.125 B0.063–0.25 B0.063 0.25 B0.063–0.5 0.125 0.25 0.125–0.25 0.25 0.25 B0.063–0.25
CFPN B0.063 1 B0.063–2 0.5 1 B0.063–1 2 2 0.5–2 2 2 0.5–2
CPDX B0.063 2 B0.063–4 1 2 B0.063–2 4 4 2–4 2 4 2–4
CFDN 0.25 2 0.125–4 1 4 0.25–4 4 8 2–8 4 8 2–8
CFTM B0.063 0.5 B0.063–0.5 0.5 0.5 B0.063–0.5 0.5 1 0.5–1 0.5 1 0.25–1
CTM 2 32 0.5–64 4 16 0.5–16 64 128 8–128 32 64 8–128
CTRX B0.063 0.25 B0.063–0.25 B0.063 0.25 B0.063–0.25 0.25 0.25 0.125–0.25 0.25 0.25 B0.063–0.5
CTX B0.063 0.5 B0.063–1 0.25 0.5 B0.063–1 1 1 0.5–1 1 1 0.25–1
AZM 1 2 0.5–64 0.5 1 0.25–1 1 64 0.5–64 1 2 0.5–4
CAM 8 8 2 to[64 4 8 2–8 4 [64 4 to[64 8 16 4–16
RKM 8 16 4–16 4 8 1–8 2 8 2–8 8 8 2–16
TEL 2 4 1–4 – – – 1 8 1–8 – – –
FRPM 0.5 2 0.125–2 0.5 2 B0.063–4 2 2 2–2 2 4 1–4
TBPM – – – B0.063 0.5 B0.063–0.5 – – – 0.5 1 B0.063–2
PAPM 0.5 2 B0.063–2 0.25 4 B0.063–4 1 4 0.5–4 2 8 0.25–8
MEPM B0.063 0.25 B0.063–0.5 B0.063 0.25 B0.063–0.25 0.125 0.25 B0.063–0.25 0.25 0.5 B0.063–1
DRPM – – – 0.125 1 B0.063–1 – – – 1 2 B0.063–2
LVFX B0.063 B0.063 B0.063–B0.063 B0.063 B0.063 B0.063–B0.063 B0.063 0.25 B0.063–0.25 B0.063 B0.063 B0.063–B0.063
TFLX – – – B0.063 B0.063 B0.063–B0.063 – – – B0.063 B0.063 B0.063–B0.063
ABPC ampicillin, CVA/AMPC clavulanic acid/amoxicillin, PIPC piperacillin, TAZ/PIPC tazobactam/piperacillin, CCL cefaclor, CDTR cefditoren, CFPN cefcapene, CPDX cefpodoxime, CFDN cefdinir, CFTM cefteram, CTM
cefotiam, CTRX ceftriaxone, CTX cefotaxime, AZM azithromycin, CAM clarithromycin, RKM rokitamycin, TEL telithromycin, FRPM faropenem, TBPM tebipenem, PAPM panipenem, MEPM meropenem, DRPM doripenem, LVFX
levoﬂoxacin, TFLX tosuﬂoxacin
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genetic methods [8]. Owing to the widespread use of
guidelines in the pediatric ﬁeld [9, 10], the proper use of
antimicrobial agents may have been promoted in Japan.
In contrast to the decline in the number of BLNAR
strains, the number of b-lactamase-producing strains,
which had continued to decrease, from 8.3 % in phase 1 to
6.4 % in phase 2, and to 4.4 % in phase 3, increased to
8.7 % in phase 4. This difference was greatly inﬂuenced by
the BLPACR strains, whose number increased from 1.6 %
in phase 3 to 4.8 % in phase 4. The BLPACR strains,
which have two mechanisms of antimicrobial resistance
that comprise b-lactamase production and mutations in ftsI
genes, show resistance to many b-lactams. High detection
rates of BLPACR strains have been reported in France
(13.9 %) from 1999 to 2000 [11] and in Spain (22.4 %)
from 2005 to 2007 [12], and in some cases clonal dis-
semination of the BLPACR strains has been observed [12,
13]. A similar phenomenon may have happened in Japa-
nese children; analysis of clonality using multilocus
sequence typing or pulsed-ﬁeld gel electrophoresis method
will thus be required to explain the increase of BLPACR
strains.
The BLNAR strains, which have mutations in the ftsI
genes that make PBP3 with poor afﬁnity for antimicrobial
agents, showed reduced susceptibility to various types of
b-lactams including cephems [2]. When the number of
BLNAR strains rapidly increased between phase 1 and
phase 2, the MIC90 values of most b-lactams showed a
corresponding 2- to 4 fold increase [3]. On the other hand,
the BLNAR strains showed a trend toward improved
susceptibility after phase 2, when the number of BLNAR
strains decreased and the MIC90 value of each b-lactam
antimicrobial agent decreased from one half to one fourth
between phase 2 and phase 3. There were no increases in
MIC90 values of b-lactams between phase 3 and phase 4
with the exception of CDTR, CFPN, and PAPM, which
showed a 2-fold increase. However, the MIC90 values of
b-lactams in BLNAR strains were 2- to 4 fold higher in
Table 3 Number of cases of b-lactamase-nonproducing ABPC-sensitive strain (BLNAS) or b-lactamase-nonproducing ABPC-intermediately
resistant strain (BLNAI) ? b-lactamase-nonproducing ABPC-resistant strain (BLNAR) according to background factor
Background factor Phase 3 Phase 4
Number of cases Statistics Number of cases Statistics
BLNAS BLNAI ? BLNAR BLNAS BLNAI ? BLNAR
Sex
Boy 78 123 v2 91 152 v2
Girl 46 111 P = 0.0607 70 128 P = 0.6495
Age category
Infant 26 40 v2 28 74 v2
Toddler 91 177 P = 0.4703 122 196 P = 0.0546
Schoolchild 13 17 11 11
Sibling/siblings
Yes 80 144 v2 94 179 v2
No 51 91 P = 0.9688 67 102 P = 0.2684
Group daycare
Yes 78 141 v2 88 147 v2
No 48 83 P = 0.8467 70 108 P = 0.6972
Group daycare (siblings)
Yes 62 114 v2 70 122 v2
No 8 16 P = 0.8552 21 37 P = 0.9722
Previous use of antimicrobial agents
Yes 58 139 v2 87 176 v2
No 75 97 P = 0.0047 74 105 P = 0.0765
Penicillins 8 29 20 46
Cephems 29 85 36 93
Macrolides 21 55 40 74
b-Lactam 36 103 v2 53 123 v2
Macrolides 21 55 P = 0.7832 40 74 P = 0.3754
ABPC ampicillin
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phase 3 and 2- to 8 fold higher in phase 4, when compared
with BLNAS strains. As BLNAR strains show lower
susceptibility to most oral b-lactams, it is considered that
limited treatment options will continue to be a particular
problem.
In this study, the antimicrobial agents with the lowest
MIC90 were LVFX in phase 3 and LVFX and TFLX in
phase 4. Fluoroquinolones, which are not affected by
mutations in ftsI genes, showed lower MIC50 and MIC90
values of B0.063 lg/ml for the BLNAR strains. Although
the MIC of LVFX was continuously measured in phases 3
and 4, no reduced susceptibility was observed. However,
the emergence of ﬂuoroquinolone-resistant H. inﬂuenzae
strains has been detected in adult patients who use ﬂuo-
roquinolones frequently [14]. Treatment with TFLX in
pediatric patients with otitis media or pneumonia has been
covered by insurance since 2009; the use of ﬂuoroquino-
lones in pediatric patients can thus be expected to increase
steadily. The proper use of ﬂuoroquinolones is extremely
important if we are to prevent ﬂuoroquinolone-resistant
strains from spreading in pediatric patients.
In Japan, Hib vaccine was introduced as a voluntary
vaccination in December 2008, between phases 3 and 4.
Two years after its introduction, at the end of 2010, pub-
licly subsidized vaccines became available, and since then
the incidence of invasive Hib infection has decreased
because of an improvement in the vaccination rate [15]. In
our study, 14 (3.6 %) and 23 Hib strains (4.8 %) were
isolated in phase 3 and phase 4, respectively, indicating no
decrease in the number of Hib cases after the introduction
of the vaccine. However, the strains in phase 4 were
acquired between January and June 2010, before the ini-
tiation of the publicly subsidized vaccine program; it is
likely that the Hib vaccine was not then widely available.
We will have to wait for the next phase of surveillance to
conﬁrm the effect of vaccination on Hib detection rates.
During phase 1 and phase 2 surveillance, the relation-
ship between three background factors (age, prior admin-
istration of antimicrobial agents, and attendance at a
daycare center) and the isolation rate of drug-resistant
strains was examined, and there were signiﬁcant differ-
ences in age and prior administration of antimicrobial
agents in phase 2 [3]. In this study, in relationship to a total
of six background factors, including the three factors from
the previous study and three additional factors (sex, sib-
lings, and siblings’ attendance at a daycare center), there
were signiﬁcant differences as regards prior administration
of antimicrobial agents in phase 3.
In phase 3, the isolation rate of drug-resistant strains was
high in those cases with prior administration of antimi-
crobial agents. In phase 2, there were differences related to
the types of antimicrobial agents; the frequency of drug-
resistant strains in the cases treated with b-lactams was
higher than that in the cases treated with macrolides, while
no differences were observed in phase 3. Although the
mutations in PBP3 in the BLNAR strains are considered to
be easily induced by the abuse of the oral cephems [2], no
signiﬁcant difference was found among penicillins, cep-
hems, and macrolides. It is likely that each type of anti-
microbial agent was prescribed in a balanced manner.
In relationship to other background factors, no signiﬁ-
cant difference was found in the frequency of drug-resis-
tant strains. In phase 2, the isolation rate of drug-resistant
strains was signiﬁcantly higher in children under 3 years of
age, while no such difference was found in phases 3 and 4
(data not shown). As there was also an apparent decrease in
the number of the BLNAR strains in infants, similar future
transitions deserve attention.
It has been 10 years since the establishment of this
group. We would like to continue conducting surveillance
so that we can provide useful information on the drug
resistance of H. inﬂuenzae for use in clinical practice.
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